ArticleCells2019

Preclinical Evaluation of the Pan-FGFR Inhibitor LY2874455 in FRS2-Amplified Liposarcoma.

Robert Hanes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.